Evidence map›Paper›PMID 36597532›Full record

ArticlemedRxiv : the preprint server for health sciences2022

SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia.

Kai Qin, Kazuhito Honjo, Scott Sherrill-Mix, Weimin Liu, Regina Stoltz, Allisa K Oman, Lucinda A Hall, Ran Li, Sarah Sterrett, Ellen R Frederick and 13 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Kai QinDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Kazuhito HonjoDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Scott Sherrill-MixDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Weimin LiuDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Regina StoltzDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Allisa K OmanDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Lucinda A HallDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Ran LiDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Sarah SterrettDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Ellen R FrederickDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Jeffrey R LancasterDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Mayur NarkhedeDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Amitkumar MehtaDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Foluso J OgunsileDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Rima B PatelDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Thomas J KetasDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA.
Victor M Cruz PortilloDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA.
Albert CupoDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA.
Benjamin M LarimerDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Anju BansalDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Paul A GoepfertDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Beatrice H HahnDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Randall S DavisDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
University of Alabama at Birmingham · USUniversity of Pennsylvania · USCornell University · US

Funding

A-Z Clinical Trials UnitUM1AI069452 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 2012 to 2026
$28.8M
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogensR37AI150590 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Beatrice H Hahn · 2019 to 2026
$6.9M
Project-002U01CA260462 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BOPPANA, SURESH B, BRITT, WILLIAM JARVIS · 2020 to 2023
$4.0M
NCI NIH HHS U01 CA260462NIAID NIH HHS R37 AI150590NIAID NIH HHS UM1 AI069452
6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) patients have lower seroconversion rates and antibody titers following SARS-CoV-2 vaccination, but the reasons for this diminished response are poorly understood. Here, we studied humoral and cellular responses in 95 CLL patients and 30 healthy controls after two BNT162b2 or mRNA-2173 mRNA immunizations. We found that 42% of CLL vaccinees developed SARS-CoV-2-specific binding and neutralizing antibodies (NAbs), while 32% had no response. Interestingly, 26% were seropositive, but had no detectable NAbs, suggesting the maintenance of pre-existing endemic human coronavirus-specific antibodies that cross-react with the S2 domain of the SARS-CoV-2 spike. These individuals had more advanced disease. In treatment-naïve CLL patients, mRNA-2173 induced 12-fold higher NAb titers and 1.7-fold higher response rates than BNT162b2. These data reveal a graded loss of immune function, with pre-existing memory being preserved longer than the capacity to respond to new antigens, and identify mRNA-2173 as a superior vaccine for CLL patients.

Identifiers

PMID36597532
PMCPMC9810225
OpenAlexW4313451808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.